Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07009899 · ClinicalTrials.gov registry record · Phase 2
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07009899: Clinical Trial Phase 2 study, sponsored by Medical College of Wisconsin.
NCT07009899 is a Phase 2 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07009899, a Phase 2 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or investigational.
Primary Outcome
This is the number of subjects who have a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.
Interventions
- DRUG Linvoseltamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What is known before NCT07009899 opens enrollment
NCT07009899 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Linvoseltamab is the first listed.
NCT07009899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07009899 about?
NCT07009899 is a clinical study titled "BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)". This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or investigational.
What is the current status of trial NCT07009899?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-07-01. Estimated completion is 2029-02-01.
What interventions are being tested in trial NCT07009899?
The interventions under investigation include: Linvoseltamab (DRUG).
Who is sponsoring clinical trial NCT07009899?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07009899's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI